Markers for the development of early prostate cancer

Journal of Pathology

Volumn 199, Issue 3, 2003, Pages 368-377

  Slater, Michael D ^a,b   Lauer, Christopher ^c   Gidley Baird, Angus ^a,b   Barden, Julian A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Bioquest   (Australia)

^c Missenden Medical Centre   (Australia)

Author keywords

Cell adhesion; E cadherin; Prostate cancer; Purinergic; Telomerase; Tenascin

Indexed keywords

EOSIN; HEMATOXYLIN; PROSTATE SPECIFIC ANTIGEN; PURINE RECEPTOR; TELOMERASE; TENASCIN; TUMOR ANTIGEN; UVOMORULIN;

ACINAR CELL; ADULT; AGED; ANTIGEN RETRIEVAL; BASEMENT MEMBRANE; CANCER GROWTH; CANCER TISSUE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EARLY CANCER; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PH MEASUREMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVIEW; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; CADHERINS; CARRIER PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, PURINERGIC; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0037373168     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1258     Document Type: Review

References (43)

1. Kammerer R, Ehret R, von Kleist S. Isolated extracellular matrixbased three-dimensional in vitro models to study orthotopically cancer cell infiltration and invasion. Eur J Cancer 1998; 34: 1950-1957.
2. Kedeshian P, Sternlicht MD, Nguyen M, Shao ZM, Barsky SH. Humatrix, a novel myoepithelial matrical gel with unique biochemical and biological properties. Cancer Lett 1998; 123: 215-226.
3. Xue Y, Li J, Latijnhouwers MA, et al. Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Br J Urol 1998; 81: 844-851.
4. Pilch H, Schaffer U, Schlenger K, et al. Expression of tenascin in human cervical cancer - association of tenascin expression with clinicopathological parameters. Gynecol Oncol 1999; 73: 415-421.
5. Doi D, Araki T, Asano G. Immunohistochemical localization of tenascin, estrogen receptor and transforming growth factor-beta 1 in human endometrial carcinoma. Gynecol Obstet Invest 1996; 41: 61-66.
6. Davidson B, Goldberg I, Gotlieb WH, Ben-Baruch G, Kopolovic J. Expression of matrix proteins in uterine cervical neoplasia using immunohistochemistry. Eur J Obstet, Gynecol, Reprod Biol 1998; 76: 109-114.
7. Karja V, Syrjanen K, Syrjanen S. Collagen IV and tenascin immunoreactivity as prognostic determinant in benign and malignant salivary gland tumours. Acta Oto-Laryngol 1995; 115: 569-575.
8. Nerlich AG, Wiest I, Wagner E, Sauer U, Schleicher ED. Gene expression and protein deposition of major basement membrane components and TGF-beta 1 in human breast cancer. Anticancer Res 1997; 17: 4443-4449.
9. Kusagawa H, Onoda K, Namikawa S, et al. Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer 1998; 77: 98-102.
10. Iskaros BF, Tanaka KE, Hu X, Kadish AS, Steinberg JJ. Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer. J Surg Oncol 1997; 64: 98-101.
11. Phillips GR, Krushel LA, Crossin KL. Domains of tenascin involved in glioma migration. J Cell Sci 1998; 111: 1095-1104.
12. Julian J, Chiquet-Ehrismann R, Erickson HP, Carson DD. Tenascin is induced at implantation sites in the mouse uterus and interferes with epithelia cell adhesion. Development 1994; 120: 661-671.
13. Yoshida T, Yoshimura E, Numata H, Sakakura Y, Sakakura T. Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells. Virchows Arch 1999; 435: 496-500.
14. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 1997; 73: 10-15.
15. Tokes AM, Hortovanyi E, Csordas G, et al. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. Anticancer Res 1999; 19: 175-179.
16. Chung C, Erickson H. Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. J Cell Sci 1997; 110: 1413-1419.
17. Cohen MB, Griebling TL, Ahaghotu CA, Rokhlin OW, Ross JS. Cellular adhesion molecules in urologic malignancies. Am J Clin Pathol 1997; 107: 56-63.
18. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA. Complex cadherin expression in human prostate cancer cells. Int J Cancer 2000; 85: 446-450.
19. Tran NL, Nagle RB, Cress AE, Heimark RL. N-cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol 1999; 155: 787-798.
20. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997; 33: 263-271.
21. Bryden AA, Freemont AJ, Clarke NW, George NJ. Paradoxical expression of E-cadherin in prostatic bone metastases. BJU Int 1999; 84: 1032-1034.
22. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumour aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999; 53: 707-713.
23. Kuniyasu H, Troncoso P, Johnston D, et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000; 6: 2295-2308.
24. Ruijter E, van de Kaa C, Aalders T, et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 1998; 11: 276-281.
25. Kuczyk M, Serth J, Machtens S, et al. Expression of E-cadherin in primary prostate cancer: correlation with clinical features. Br J Urol 1998; 81: 406-412.
26. Morales C, Holt S, Ouellette M. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genet 1999; 21: 115-118.
27. Matthews P, Jones C. Clinical implications of telomerase detection. Histopathology 2001; 38: 485-498.
28. Slater M, Delprado WJ, Murphy CR, Barden JA. Detection of preneoplasia in histologically normal prostate biopsies. Prostate Cancer Prostatic Dis 2001; 4: 92-96.
29. Lin Y, Uemura H, Fujinami K, et al. Detection of telomerase activity in prostate needle-biopsy samples. Prostate 1998; 36: 121-128.
30. Ueda M, Ouhtit A, Bito T. Evidence for UV-associated activation of telomerase in human skin. Cancer Res 1997; 57: 370-374.
31. Mokbel K, Parris C, Ghilchik M, Williams G, Newbold R. The association between telomerase, histological parameters, and KI-67 expression in breast cancer. Am J Surg 1999; 178: 69-72.
32. Harrington L, McPhail T, Mar V, et al. A mammalian telomerase-associated protein. Science 1997; 275: 973-977.
33. Barden JA, Cuthbertson RM, Jia-Zhen W, Moseley JM, Kemp BE. Solution structure of PTHrP(Ala15)(1-34). J Biol Chem 1997; 272: 29 572-29578.
34. Slater M. Mitochondrial DNA damage assessment using fluorescence microscopy quantitation. J Histotechnol 1999; 22: 17-21.
35. Slater M, Murphy CR. Detection of apoptotic DNA damage in prostate hyperplasia using tyramide-amplified avidin-HRP. Histochem J 1999; 31: 747-749.
36. Foster CS, Bostwick DG, Bonkhoff H, et al. Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol Suppl 2000; 205: 19-43.
37. De Matzo AM, Nelson WG, Meeker AK, Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998; 160: 2381-2392.
38. Tapia-Vieyra JV, Mas-Oliva J. Apoptosis and cell death channels in prostate cancer. Arch Med Res 2001; 32: 175-185.
39. Kirkman W 3rd, Chen P, Schroeder R, et al. Transduction and apoptosis induction in the rat prostate, using adenovirus vectors. Hum Gene Ther 2001; 12: 1499-1512.
40. Cotran R, Kumar V, Collins T. Pathological Basis of Disease (6th edn). WB Saunders: New York, 1999.
41. Kelley MR, Cheng L, Foster R, et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 2001; 7: 824-830.
42. Bull JH, Ellison G, Patel A, et al. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 2001; 84: 1512-1519.
43. Bova GS, Parmigiani G, Epstein JI, Wheeler T, Mucci NR, Rubin MA. Web-based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading. Hum Pathol 2001; 32: 417-427.